DiaMedica Therapeutics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of DiaMedica Therapeutics (DMAC) with a Buy rating and no price target The firm says the interim proof of concept data indicates DM199 does not cross the placenta and is a potent vasodilator in preeclampsia, with early signs of enhanced placental perfusion. Key opinion leaders are “enthusiastic” for the potential to treat both hypertension and endothelial dysfunction to drastically improve maternal-fetal outcomes, the analyst tells investors in a research note. TD sees potential $1B in peak sales in early onset preeclampsia alone.